GLP-1/GIP dual agonists
GLP-1/GIP dual agonists activate two incretin hormone receptors at once — the mechanism behind tirzepatide, whose weight-loss results reset expectations for the category and pulled drug development toward multi-agonism.
- Dual incretin action: GLP-1 plus GIP receptors
- Tirzepatide is the approved dual agonist
- Outperformed single agonists in weight-loss trials
- Direction of the field: multi-receptor agonism
Why add GIP to GLP-1
GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone. Combining GIP activity with GLP-1 agonism produced greater average weight reduction in trials than GLP-1 alone — tirzepatide’s SURMOUNT results ran well beyond semaglutide’s benchmarks — and established multi-receptor design as the direction of the field: dual agonists today, triple agonists like retatrutide in late-stage development.
Program-design implications
For operators, dual agonists mean a two-tier catalog: patients and clinicians increasingly arrive asking for the strongest option, price and coverage differ by molecule, and titration schedules are molecule-specific. The practical requirements are unchanged — clinician judgment on which therapy fits, refill logic per product, and supply-channel management — but catalog breadth becomes a real competitive surface as the class fragments.
What the trials actually showed
In STEP trials, semaglutide averaged roughly 15% body-weight reduction over 68 weeks; in SURMOUNT, tirzepatide’s top dose averaged about 21% over 72 weeks. These are different trials with different populations — not a head-to-head — but the gap was large enough to reset patient expectations and payer conversations. Clinically, therapy selection still weighs tolerability, comorbidities, coverage, and cost; the strongest molecule on paper is not automatically the right one for a given patient.
Single vs dual, operationally
| Dimension | GLP-1 (semaglutide) | GLP-1/GIP (tirzepatide) |
|---|---|---|
| Trial benchmark | ~15% avg (STEP) | ~21% avg (SURMOUNT) |
| Patient demand | Established, broad | Arrives pre-anchored on Zepbound |
| Cash channels | NovoCare direct pricing | LillyDirect vials |
| Titration | Molecule-specific ladder | Molecule-specific ladder |
| Program takeaway | Volume workhorse | The efficacy benchmark |
The branded products
| Brand | Maker | Indication | Form |
|---|---|---|---|
| Mounjaro | Eli Lilly | Type 2 diabetes | Weekly injection |
| Zepbound | Eli Lilly | Weight management + sleep apnea | Weekly injection (pens and LillyDirect vials) |
Compliance handled, so you can build
Lithos runs the clinicians, pharmacies, and 50-state rules behind your care program — one API.
Frequently asked questions
Is a dual agonist better than a GLP-1?
Trials showed greater average weight loss for tirzepatide, but the right therapy per patient is a clinical decision balancing response, tolerability, coverage, and cost.
What products are dual agonists?
Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for weight management.
What comes after dual agonists?
Triple agonists adding glucagon-receptor activity — retatrutide is the most-watched late-stage candidate — plus oral formulations across the class.